GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pharmaids Pharmaceuticals Ltd (BOM:524572) » Definitions » Piotroski F-Score

Pharmaids Pharmaceuticals (BOM:524572) Piotroski F-Score : 3 (As of Mar. 25, 2025)


View and export this data going back to 2001. Start your Free Trial

What is Pharmaids Pharmaceuticals Piotroski F-Score?

Warning Sign:

Piotroski F-Score of 3 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Pharmaids Pharmaceuticals has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Pharmaids Pharmaceuticals's Piotroski F-Score or its related term are showing as below:

BOM:524572' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 4   Max: 8
Current: 3

During the past 13 years, the highest Piotroski F-Score of Pharmaids Pharmaceuticals was 8. The lowest was 1. And the median was 4.


Pharmaids Pharmaceuticals Piotroski F-Score Historical Data

The historical data trend for Pharmaids Pharmaceuticals's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmaids Pharmaceuticals Piotroski F-Score Chart

Pharmaids Pharmaceuticals Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.00 7.00 5.00 3.00 3.00

Pharmaids Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 3.00 - - -

Competitive Comparison of Pharmaids Pharmaceuticals's Piotroski F-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Pharmaids Pharmaceuticals's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharmaids Pharmaceuticals's Piotroski F-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Pharmaids Pharmaceuticals's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Pharmaids Pharmaceuticals's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Net Income was ₹-79.7 Mil.
Cash Flow from Operations was ₹-106.2 Mil.
Revenue was ₹146.0 Mil.
Gross Profit was ₹17.0 Mil.
Average Total Assets from the begining of this year (Mar23)
to the end of this year (Mar24) was (245.847 + 913.407) / 2 = ₹579.627 Mil.
Total Assets at the begining of this year (Mar23) was ₹245.8 Mil.
Long-Term Debt & Capital Lease Obligation was ₹60.5 Mil.
Total Current Assets was ₹135.3 Mil.
Total Current Liabilities was ₹115.8 Mil.
Net Income was ₹-75.6 Mil.

Revenue was ₹0.0 Mil.
Gross Profit was ₹-8.9 Mil.
Average Total Assets from the begining of last year (Mar22)
to the end of last year (Mar23) was (111.123 + 245.847) / 2 = ₹178.485 Mil.
Total Assets at the begining of last year (Mar22) was ₹111.1 Mil.
Long-Term Debt & Capital Lease Obligation was ₹0.0 Mil.
Total Current Assets was ₹183.2 Mil.
Total Current Liabilities was ₹21.2 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Pharmaids Pharmaceuticals's current Net Income (TTM) was -79.7. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Pharmaids Pharmaceuticals's current Cash Flow from Operations (TTM) was -106.2. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar23)
=-79.68/245.847
=-0.32410402

ROA (Last Year)=Net Income/Total Assets (Mar22)
=-75.557/111.123
=-0.67994025

Pharmaids Pharmaceuticals's return on assets of this year was -0.32410402. Pharmaids Pharmaceuticals's return on assets of last year was -0.67994025. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Pharmaids Pharmaceuticals's current Net Income (TTM) was -79.7. Pharmaids Pharmaceuticals's current Cash Flow from Operations (TTM) was -106.2. ==> -106.2 <= -79.7 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar23 to Mar24
=60.529/579.627
=0.1044275

Gearing (Last Year: Mar23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar22 to Mar23
=0/178.485
=0

Pharmaids Pharmaceuticals's gearing of this year was 0.1044275. Pharmaids Pharmaceuticals's gearing of last year was 0. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar24)=Total Current Assets/Total Current Liabilities
=135.32/115.758
=1.16899048

Current Ratio (Last Year: Mar23)=Total Current Assets/Total Current Liabilities
=183.155/21.247
=8.6202758

Pharmaids Pharmaceuticals's current ratio of this year was 1.16899048. Pharmaids Pharmaceuticals's current ratio of last year was 8.6202758. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Pharmaids Pharmaceuticals's number of shares in issue this year was 22.718. Pharmaids Pharmaceuticals's number of shares in issue last year was 12.896. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=16.977/145.971
=0.11630392

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=-8.876/0
=

Pharmaids Pharmaceuticals's gross margin of this year was 0.11630392. Pharmaids Pharmaceuticals's gross margin of last year was . ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar23)
=145.971/245.847
=0.59374733

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar22)
=0/111.123
=0

Pharmaids Pharmaceuticals's asset turnover of this year was 0.59374733. Pharmaids Pharmaceuticals's asset turnover of last year was 0. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+0+0+0+0+1+1
=3

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Pharmaids Pharmaceuticals has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

Pharmaids Pharmaceuticals  (BOM:524572) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Pharmaids Pharmaceuticals Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Pharmaids Pharmaceuticals's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharmaids Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
HMT Factory Road, Unit 201, Brigade Rubix, 20/14, Peenya Plantation, Bangalore, KA, IND, 560013
Pharmaids Pharmaceuticals Ltd is an India-based pharmaceutical company. It is mainly engaged in the business contract research and manufacturing services. The products are offered in the areas of hospital care products, skin care products, specialty chemicals, and others. It generates revenue from the sale of its products.

Pharmaids Pharmaceuticals Headlines

No Headlines